London · Delayed Price · Currency is GBP · Price in GBX Verici Dx Earnings Call Transcripts
Fiscal Year 2025
-
RNA-based transplant tests achieved 32% Q1 revenue growth, with 29 U.S. centers now ordering and strong Medicare coverage. Recent equity raises extend cash runway, while a clear path to profitability is set at GBP 60 million annual sales.
-
Medicare coverage for Tutivia and a successful GBP 6.3 million fundraise enabled commercial expansion, with revenues recognized and a strong cash runway. Growth is expected from new center onboarding and an expanded sales team, with 2025 revenue targets maintained.
Fiscal Year 2024
-
Revenue reached $3.3M in H1, driven by licensing and services, with strong cost control and a $7M cash balance. Tutivia expansion and ProTega validation are on track, with diversified revenue streams and a robust pipeline supporting long-term growth.